[Human growth hormone and Turner syndrome]

An Pediatr (Barc). 2017 Feb;86(2):81-86. doi: 10.1016/j.anpedi.2016.02.009. Epub 2016 May 11.
[Article in Spanish]

Abstract

Objective: The evaluation of clinical and analytical parameters as predictors of the final growth response in Turner syndrome patients treated with growth hormone.

Material and methods: A retrospective study was performed on 25 girls with Turner syndrome (17 treated with growth hormone), followed-up until adult height. Auxological, analytical, genetic and pharmacological parameters were collected. A descriptive and analytical study was conducted to evaluate short (12 months) and long term response to treatment with growth hormone.

Results: A favourable treatment response was shown during the first year of treatment in terms of height velocity gain in 66.6% of cases (height-gain velocity >3cm/year). A favourable long-term treatment response was also observed in terms of adult height, which increased by 42.82±21.23cm (1.25±0.76 SDS), with an adult height gain of 9.59±5.39cm (1.68±1.51 SDS).

Conclusions: Predictors of good response to growth hormone treatment are: A) initial growth hormone dose, B) time on growth hormone treatment until starting oestrogen therapy, C) increased IGF1 and IGFBP-3 levels in the first year of treatment, and D) height gain velocity in the first year of treatment.

Keywords: Growth hormone; Hormona de crecimiento; Short stature; Síndrome de Turner; Talla baja; Turner syndrome.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Infant
  • Recombinant Proteins / therapeutic use
  • Retrospective Studies
  • Turner Syndrome / drug therapy*

Substances

  • Recombinant Proteins
  • Human Growth Hormone